CD4 News and Research

RSS

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Researchers in the United States have conducted a study suggesting that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit better neutralizing activity against variants of concern following vaccination against coronavirus disease 2019 (COVID-19) than previously uninfected vaccinees.

19 Jul 2021

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

Researchers in the United States have conducted a study showing that the coronavirus disease 2019 (COVID-19) vaccines developed by Pfizer-BioNTech and Moderna generate a coordinated adaptive immune response that is capable of eliciting recall responses to future infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jul 2021

How do immunocompromised patients respond to COVID-19 vaccines?

The COVID-19 vaccines produce a boost in antibody activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, new research suggests vaccine responses aren’t all created equal. Their findings showed that immunocompromised patients, such as transplant recipients, with no prior exposure to SARS-CoV-2 produce little to no neutralizing antibodies.

18 Jul 2021

Colonization by SARS-CoV-2 not synonymous with infection, screening study highlights

A new study released as a preprint on the medRxiv* server throws cold water on this notion, however, by demonstrating that in a set of asymptomatic cases, less than a tenth actually had evidence of SARS-CoV-2 infection. This finding has serious implications for the practices mentioned above, since they may be neither justifiable nor cost-effective as means to break the chain of viral transmission.

13 Jul 2021

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

A recent study published in the MDPI journal, Pathogens, describes a coronavirus peptide vaccine antigen in the form of nanodiamond-based formulations, that demonstrated a robust and long-lasting immune response. The nanodiamonds proved to be a powerful and versatile platform for antigen conjugation. This could make it a safe and effective strategy for the production of off-the-shelf vaccines against multiple coronaviruses.

13 Jul 2021

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Researchers from Switzerland recently investigated humoral and cell-mediated immune responses to mRNA-based vaccines in patients undergoing treatment with CD20-B-cell depleting agents for autoimmune diseases, transplantation, or malignancy.

12 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Changes to COVID-19 vaccination strategy could speed up herd immunity

Researchers in the United States have proposed changes to the current coronavirus disease 2019 (COVID-19) vaccination strategy that they say would increase the likelihood of herd immunity being achieved in the most timely and cost-effective manner.

8 Jul 2021

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Researchers in the United States have shown that Moderna’s mRNA-1273 coronavirus disease 2019 (COVID-19) vaccine induces durable antibody and T cell responses to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that are comparable to those seen in cases of COVID-19 caused by natural SARS-CoV-2 infection.

6 Jul 2021

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

Researchers in the Netherlands have conducted a study showing that Janssen’s Ad26.COV2.S coronavirus disease 2019 (COVID‐19) vaccine was effective against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among eight individuals.

4 Jul 2021

B cell depleting agents can cause altered immune responses to COVID-19 vaccines, suggests study

A new preprint, available on the medRxiv* server, describes altered responses to the use of the highly effective messenger RNA (mRNA) vaccines from Pfizer/BioNTech and Moderna in patients with multiple sclerosis on anti-CD20 (MS-aCD20) monotherapy.

2 Jul 2021

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the treatment could be used to restore cellular immune function and suppress SARS-CoV-2.

1 Jul 2021

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

Researchers at La Jolla Institute for Immunology have found that T cells from people who have recovered from COVID-19 or received the Moderna or Pfizer-BioNTech vaccines are still able to recognize several concerning SARS-CoV-2 variants.

1 Jul 2021

What's behind COVID-19 vaccine side effects?

A growing concern among coronavirus vaccines is the vaccine side effects. Fear or misinformation about side effects may fuel vaccine hesitancy, contributing to low vaccination rates. Australian researchers recently published an article in Science Immunology to discuss why people develop side effects and their benefits.

28 Jun 2021

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Researchers compared peripheral blood mononuclear cells in people with high and low antibody titers after two doses of the Pfizer/BioNTech (BNT162b2) mRNA vaccine. They found a positive correlation between naïve B cells present before vaccination and high antibody titers.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

CD4 News and Research

Past SARS-CoV-2 infection enhances mRNA vaccine-induced neutralization of variants of concern

Pfizer-BioNTech and Moderna COVID-19 vaccines establish recall responses to reinfection

How do immunocompromised patients respond to COVID-19 vaccines?

Colonization by SARS-CoV-2 not synonymous with infection, screening study highlights

“React and inject”: synthetic peptide-modified nanodiamonds as emergency pan-coronavirus vaccines

SARS-CoV-2 mRNA vaccine efficacy reduced in patients with CD20-B-cell depleting treatment history

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

Changes to COVID-19 vaccination strategy could speed up herd immunity

Moderna’s COVID-19 vaccine elicits durable T cell memory and antibody responses

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

B cell depleting agents can cause altered immune responses to COVID-19 vaccines, suggests study

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

Study highlights the importance of T cell cross reactivity in stopping severe COVID-19 infections

What's behind COVID-19 vaccine side effects?

Study associates higher antibody titers with naïve B cells post-mRNA vaccination

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

TET enzymes play key role in keeping immune cells on a healthy track

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

CD39+ monocyte count higher in pregnant than non-pregnant COVID-19 patients

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News